Dehydroepiandrosterone sulfate (DHEAS) and testosterone: Relation to HIV illness stage and progression over one year

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 22, Issue 2, 1999, Pages 146-154

  Ferrando, Stephen J ^a,b   Rabkin, Judith G ^a   Poretsky, Leonid ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

AIDS; Dehydroepiandrosterone sulfate; HIV infection; Testosterone; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; STERYL SULFATASE; TESTOSTERONE;

ADULT; ARTICLE; DEPRESSION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; FATIGUE; HORMONAL REGULATION; HORMONE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL; VIRUS LOAD;

HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0032725412     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-199910010-00006     Document Type: Article

References (48)

1. Poretsky L, Can S, Zumoff B. Testicular dysfunction in human immunodeficiency virus-infected men. Metabolism 1995;44:946-53.
2. Dobs AS, Dempsey MA, Ladenson PW, Polk, BF. Endocrine disorders in men infected with human immunodeficiency virus. Am J Med 1988;84:611-16.
3. Mulder JW, Frissen PH, Krinjen P. Dehydroepiandrosterone as predictor for progression to AIDS in asymptomatic human immunodeficiency virus-infected men. J Infect Dis 1992;165:413-18.
4. Wisneiwski TL, Hilton CW, Morse EV, et al. The relationship of serum DHEA-S and cortisol levels to measures of immune function in human immunodeficiency virus-related illness. Am J Med Sci 1993;305:79-83.
5. Laudat A, Blum L, Guechot J, et al. Changes in systemic gonadal and adrenal steroids in asymptomatic human immunodeficiency virus-infected men: relationships with the CD4 cell counts. Eur J Endocrinol 1995;133:418-24.
6. Raffi F, Brisseau J, Planchon B, et al. Endocrine function in 98 HIV-infected patients: a prospective study. AIDS 1991;5:729-33.
7. Christeff N, Gharakhanian S, Thobie N, et al. Evidence for changes in adrenal and testicular steroids during HIV infection. J Acquir Immune Defic Syndr 1992;5:841-6.
8. Donovan D, Dluhy R. Endocrine disease and HIV infection. In: Bardin B, ed. Current Therapy in Endocrinology and Metabolism. New York: Mosby-Year Book, 1994:190-4.
9. Bhasin S, Bremner WJ. Emerging issues in androgen replacement therapy. J Clin Endocrinol Metab 1997;82:1-8.
10. O'Carroll R, Bancroft J. Testosterone therapy for low sexual interest and erectile dysfunction in men: a controlled study. Br J Psychiatry 1984;145:145-51.
11. Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men - a clinical research center study. J Clin Endocrinol Metab 1996;81:3469-75.
12. Bhasin S, Storer TW, Berman N, et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997;82:407-13.
13. Grinspoon S, Corcoran C, Sakari H, et al. Effects of androgen administration in men with the AIDS wasting syndrome. Ann Intern Med 1998;129:18-26.
14. Bhasin S, Storer TW, Berman N, et al. Effects of physiologic testosterone replacement with Androderm in HIV-infected men with low testosterone levels [Abstract #OR43-5]. 80th Annual Meeting of The Endocrine Society, New Orleans, LA, U.S.A., 1998.
15. Rabkin JG, Wagner G, Rabkin R. Testosterone therapy for HIV+ men with and without hypogonadism. J Clin Psychopharm 1999; 19:19-27.
16. Cofrancesco J, Whalen JJ, Dobs A. Testosterone replacement options for HIV-infected men. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:254-65.
17. Barrett-Connor E, Khaw KT, Yen SSC. A prospective study of dehydroepiandrosterone sulfate, mortality and cardiovascular disease. N Engl J Med 1986;24:1519-24.
18. Jungers P, Nahoul K, Pelissier C, et al. Low plasma androgens in women with active or quiescent systemic lupus erythematosus. Arthritis Rheum 1982;25:454-7.
19. Helzlsouer KJ, Gordon GB, Alberg AJ, et al. Relationship of pre-diagnostic serum levels of dehydroepiandrosterone and dehydro-epiandrosterone sulfate to the risk of developing premenopausal breast cancer. Cancer Res 1992;52:1.
20. Flood JF, Smith GE, Roberts E. Dehydroepiandrosterone and its sulfate enhance memory retention in mice. Brain Res 1988;447: 269-78.
21. Nasman B, Olsson T, Backstrom T, et al. Serum DHEAS in Alzheimer's disease and multi-infarct dementia. Biol Psychiatry 1991; 30:684-90.
22. Roberts E, Fauble T. Oral dehydroepiandrosterone in multiple sclerosis: results of a phase I open study. In: Kalimi M, Regelson W, eds. The biological role of dehydroepiandrosterone (DHEA). New York: Walter de Gruyter, 1990:81-93.
23. Regelson W, Kalimi M. Dehydroepiandrosterone (DHEA) - the multifunctional steroid: effects on the CNS, cell proliferation, metabolic and vascular, clinical and other effects. Mechanism of action? Ann NY Acad Sci 1994;719:564-75.
24. Wolkowitz OM, Reus VI, Roberts E, et al. Dehydroepiandrosterone (DHEA) treatment of depression. Biol Psychiatry 1997;41: 311-18.
25. Morales AJ, Nolan JJ, Nelson JC, et al. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994;78:1360-7.
26. Blauer D, Poth M, Rogers W, et al. DHA antagonizes the suppressive effects of dexamethasone on lymphocyte proliferation. Endocrinology 1991;129:3174-9.
27. Casson PR, Faquin LC, Stentz FB, et al. Replacement of dehydroepiandrosterone enhances T-lymphocyte insulin binding in post-menopausal women. Fertil Steril 1995;63:1027-31.
28. van Vollenhoven R, Engelman EG, McGuire JL. Dehydroepiandrosterone in systemic lupus erythematosus: results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheum 1995;38:1826-31.
29. Merril CR. Plasma dehydroepiandrosterone levels in HIV infection [letter]. JAMA 1989;261:1149.
30. Villette JM, Bourin P, Doinel C, et al. Circadian variations in plasma levels of hypophyseal, androcortical and testicular hormones in men infected with human immunodeficiency virus. J Clin Endocrinol Metab 1990;70:572-7.
31. Jacobson MA, Fusaro RE, Galmarini M, et al. Decreased serum dehydroepiandrosterone is associated with an increased progression of human immunodeficiency virus infection in men with CD4 cell counts 200-499. J Infect Dis 1991;164:864-8.
32. Wagner GJ, Rabkin JG. Testosterone, illness progression and megestrol use in HIV-positive men [letter]. J Acquir Immune Defic Syndr Hum Retroviol 1998;17:179-80.
33. Schurmeyer TH, Muller V, von zur Muhlen A, Schmidt RE. Endocrine testicular function in HIV-infected outpatients. Eur J Med Res 1997;2:275-81.
34. Brodt HR, Kamps BS, Gute P, Knupp B, Stasqewski S, Helm EB. Changing incidence of AIDS-defining illnesses in the era of anti-retroviral therapy. AIDS 1997;11:1731-8.
35. Pallella FJ, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
36. Rabkin JG, Ferrando SJ, Jacobsberg LB, Fishman B. Prevalence of Axis I disorders in an AIDS Cohort: a cross-sectional, controlled study. Compr Psychiatry 1997;38:1-10.
37. Parker LN. Adrenal Androgens. In: DeGroot LJ, ed. Endocrinology. Philadelphia: WB Saunders, 1995:1836-52.
38. Roubenoff R, Kahayias JJ. The meaning and measurement of lean body mass. Nutr Rev 1991;49:163-75.
39. Kotler DP, Tierney AR, Wang J, Pierson RN. Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr 1989;50:44-7.
40. [U.S.] Centers for Disease Control and Prevention: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992;41 (RR-17):1-18.
41. Rabkin JG, Williams JB, Remien RH, Goetz R, Kertzner R, Gorman J. Depression, distress, lymphocyte subsets and human immunodeficiency virus symptoms on two occasions in HIV positive homosexual men. Arch Gen Psychiatry 1991;48:111-19.
42. Perry S, Fishman B, Jacobsberg L, Frances A. Relationships over 1 year between lymphocyte subsets and psychosocial variables among adults with infection by human immunodeficiency virus. Arch Gen Psychiatry 1992;49:396-401.
43. Chalder T, Berelowitz G, Pawlikowska T, et al. Development of a fatigue scale. J Psychosom Res 1993;37:147-53.
44. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4: 53-63.
45. Piedrola G, Casado JL, Lopez E, et al. Clinical features of adrenal insufficiency in patients with acquired immunodeficiency syndrome. Clin Endocrinol 1996;45:97-101.
46. Parker LN, Levin ER, Lifrak ET. Evidence for adrenocortical adaptation to severe illness. J Clin Endocrinol Metab 1985;60:947-52.
47. Griffin JE, Wilson JD. Disorders of the testes and the male reproductive tract. In: Wilson JD and Foster DW, eds. Textbook of Endocrinology, 8th ed. Philadelphia: WB Saunders, 1995:804.
48. Bremner WJ, Vitiello MV, Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab 1983;56:1278-81.